CRSP Valuation

CRISPR Therapeutics AG

Add to Watchlist

Advanced Chart

38.430

-0.520(-1.340%)

Overview
Forecast
Valuation

CRSP Relative Valuation

CRSP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRSP is overvalued; if below, it's undervalued.

Historical Valuation

CRISPR Therapeutics AG (CRSP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 56.14 is considered Undervalued compared with the five-year average of 322.92. The fair price of CRISPR Therapeutics AG (CRSP) is between 45.45 to 54.61 according to relative valuation methord. Compared to the current price of 38.95 USD , CRISPR Therapeutics AG is Undervalued By 14.30%.

Relative Value

Fair Zone

45.45-54.61

Current Price：38.95

14.30%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.72

P/B

Median3y

2.28

Median5y

3.19

-4.35

FCF Yield

Median3y

-6.05

Median5y

-2.77

Competitors Valuation Multiple

The average P/S ratio for CRSP's competitors is 94.85, providing a benchmark for relative valuation. CRISPR Therapeutics AG Corp (CRSP) exhibits a P/S ratio of 56.14, which is -40.81% above the industry average. Given its robust revenue growth of -82.26%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

CRSP.O

CRISPR Therapeutics AG